Influences of targeted exercise therapy on treatment-related side effects of hormonetherapy in prostate cancer patients - Burgdorf-Study

Deutsche Sporthochschule zu Köln0 个研究点目标入组 60 人开始时间: 2016年2月9日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Prostate cancer patients who have received hormone therapy continuously at least over a period of 3 months and a maximum of 12 months. The treatment needs to be continue for at least one year. Half of the patients ( n = 30) received Leuprone® , the other half ( n = 30) alternative hormonal therapies.
•Serum testosterone levels < 0,50ng / ml (range castration)
•singed informed consent

•ongoing medication with tricyclic antidepressants and duloxetine (Yentreve)
•WHO / ECOG performance status> 2
•Life expectancy <6 months
•All disease situations that do not allow a sporting activity, in particular:
•Clinically manifest heart failure (NYHA III-IV)
•Respiratory partial or global failure
•Durable thrombocytopenia <10,000 / ul, for example, Autoimmunthrombozytopenien intractable.
•Congenital or acquired thrombocytopenia or any coagulation disorder.
•Symptomatic CHD (possibly performing exercise ECG is recommended)
•Severe intractable hypertension
•Not adjustable COPD
•Uncontrolled cerebral convulsions
•CNS metastases
•Medical or mental state that leads the investigator to not allowing the patient to participate in the study. or a legally binding signature of the consent form does
•Unwillingness to storage and transfer of personal data in the context of the study protocol.
•Participation in another sport-study

发起方

Deutsche Sporthochschule zu Köln